Content about Syndromes

January 15, 2014

Zafgen on Wednesday announced initial results from its Phase 2a study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome, a severe form of genetic obesity.

CAMBRIDGE, Mass — Zafgen on Wednesday announced initial results from its Phase 2a study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome, a severe form of genetic obesity. These results showed improvements in body weight, hunger-related behaviors and body composition, including reductions in body fat content and preserved lean body mass following four weeks of treatment. 

December 4, 2013

Ellen Smith has Ehlers-Danlos Syndrome (EDS), a progressive degenerative connective tissue disorder characterized by joint hypermobility, skin extensibility and tissue fragility.

Ellen Smith has Ehlers-Danlos Syndrome, a progressive degenerative connective tissue disorder characterized by joint hypermobility, skin extensibility and tissue fragility. Ellen knew from childhood that she was unusually flexible and highly mobile, but thought nothing of it. She first encountered problems as a master swimmer, when she began to have excessive shoulder pain from overstretching her ligaments. To ease the pain, she would stop swimming for a week.

December 2, 2013

Drug maker Mylan and the Elton John AIDS Foundation will donate $1 million to the Business Leadership Council for a Generation Born HIV Free, the two said.

PITTSBURGH — Drug maker Mylan and the Elton John AIDS Foundation will donate $1 million to the Business Leadership Council for a Generation Born HIV Free, the two said.

November 26, 2013

Drug maker AbbVie is launching an international awareness campaign focused on women living with HIV, the drug maker said Tuesday.

NORTH CHICAGO, Ill. – Drug maker AbbVie is launching an international awareness campaign focused on women living with HIV, the drug maker said Tuesday.

November 20, 2013

Trigg Laboratories, makers of Wet personal lubricants, will be supporting World AIDS Day on Dec. 1 through the donation of more than 5,000 safe-sex kits and samples to local clinics across nine cities to help raise awareness around HIV/AIDS, the company announced Tuesday.

LOS ANGELES — Trigg Laboratories, makers of Wet personal lubricants, will be supporting World AIDS Day on Dec. 1 through the donation of more than 5,000 safe-sex kits and samples to local clinics across nine cities to help raise awareness around HIV/AIDS, the company announced Tuesday.

August 23, 2013

HIV continues to disproportionately affect African-Americans and Hispanics, prompting a recent seminar in New York that included pop singer Alicia Keys, New York Democratic Rep. Charlie Rangel and others.

NEW YORK — While a multitude of drugs have come on the market for treating HIV, the disease continues to disproportionately affect African-Americans and Hispanics, prompting a recent seminar in New York that included pop singer Alicia Keys, New York Democratic Rep. Charlie Rangel and others.

July 8, 2013

Reporting their results July 8 in Cancer Cell, researchers say their successful laboratory tests in human MDS cells and mouse models of MDS provide a molecular target for designing new drugs to battle a syndrome with few effective treatments.

CINCINNATI — The Cincinnati Children's Hospital Medical Center announced today that scientists have successfully targeted a malfunctioning immune system enzyme to kill diseased cells from patients with myelodysplastic syndrome — a blood disorder and precursor to leukemia.

Reporting their results July 8 in Cancer Cell, researchers say their successful laboratory tests in human MDS cells and mouse models of MDS provide a molecular target for designing new drugs to battle a syndrome with few effective treatments.

June 5, 2013

The Illinois Lottery will use the net proceeds from a new game to promote HIV/AIDS education, prevention and support, the agency said Wednesday.

CHICAGO — The Illinois Lottery will use the net proceeds from a new game to promote HIV/AIDS education, prevention and support, the agency said Wednesday.

The Illinois Department of Public Health and several HIV/AIDS organizations in the state announced the launch of Spread the Word, the only lottery in the country with a game whose profits will be used exclusively to fund HIV/AIDS prevention and treatment programs.

December 21, 2012

The Food and Drug Administration has approved a drug to treat a condition that affects people who have had their intestines partially or completely removed, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug to treat a condition that affects people who have had their intestines partially or completely removed, the agency said Friday.

The FDA announced the approval of NPS Pharmaceuticals' Gattex (teduglutide) for daily injection in adults with short bowel syndrome who need additional nutrition from intravenous feeding. SBS results from partial or complete surgical removal of the small or large intestine, which can lead to poor absorption of fluids and nutrients from food.

August 20, 2012

MISSISSAUGA, Ontario — Through the support of Rexall’s vendors and partners, Rexall’s annual vendor golf classic raised more than Canadian $250,000 for the Rexall Foundation earlier this month.

The Foundation for Prader-Willi Research received a C$10,000 donation at the Aug. 14 event.  The Foundation for Prader-Willi Research is an organization dedicated to eliminating the challenges of Prader-Willi Syndrome, a rare genetic disorder, through the advancement of research.

July 16, 2012

UCB has launched a new drug for treating Parkinson's disease and restless legs syndrome, the company said Monday.

ATLANTA — UCB has launched a new drug for treating Parkinson's disease and restless legs syndrome, the company said Monday.

The Belgian drug maker announced the launch of Neupro (rotigotine) transdermal system, which the Food and Drug Administration approved in April. The drug is a once-daily patch that provides continuous delivery of rotigotine, a dopamine agonist, over 24 hours.

June 21, 2012

The Food and Drug Administration has approved a new indication for a Pfizer drug.

NEW YORK — The Food and Drug Administration has approved a new indication for a Pfizer drug.

Lyrica (pregabalin) capsules CV now can be used for the management of neuropathic pain associated with spinal cord injury. The drug received a priority review designation for this new indication as more than 100,000 patients — approximately 40% of the 270,000 patients with spinal cord injury in the United States — suffer from this chronic, complex pain condition.

April 4, 2012

The Food and Drug Administration has approved a patch for treating restless legs syndrome and Parkinson's disease.

ATLANTA — The Food and Drug Administration has approved a patch for treating restless legs syndrome and Parkinson's disease.

UCB announced the FDA approval of Neupro (rotigotine) transdermal system advanced-stage idiopathic Parkinson's and moderate-to-severe restless legs syndrome.

December 16, 2011

A drug made by Pfizer shows "significant" benefit to patients with restless legs syndrome, according to results of a late-stage clinical trial announced Friday.

NEW YORK — A drug made by Pfizer shows "significant" benefit to patients with restless legs syndrome, according to results of a late-stage clinical trial announced Friday.

The drug maker said Lyrica (pregabalin) produced statistically significant improvements in patients with RLS compared with placebo and pramipexole after 12 weeks of treatment. In the phase-3 study, A0081186, 300 mg of Lyrica, 0.25 mg of pramipexole, 0.5 mg of pramipexole or placebo was given to patients on a daily basis.

September 23, 2011

The Food and Drug Administration has approved a treatment made by Alexion Pharmaceuticals for a rare blood disorder that affects children.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment made by Alexion Pharmaceuticals for a rare blood disorder that affects children.

The FDA announced the approval of Soliris (eculizumab) for atypical hemolytic uremic syndrome, a rare and chronic disease that can lead to kidney failure, stroke and death. According to the FDA, aHUS accounts for 5% to 10% of all cases of hemolytic uremic syndrome.

September 12, 2011

Portable oral care continues to experience strong growth and, if prior sales periods are any indication of what’s ahead, the segment will likely continue to flourish.

Portable oral care continues to experience strong growth and, if prior sales periods are any indication of what’s ahead, the segment will likely continue to flourish.

Sales of portable oral care for the 52 weeks ended Aug. 7 at food, drug and mass (excluding Walmart) experienced double-digit growth, climbing 43% to $13.2 million, according to SymphonyIRI Group.

July 22, 2011

A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.

NEW YORK — A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.

May 25, 2011

Amerifit Brands on Wednesday launched its Azo PMS product, which has been formulated to help reduce moodiness, irritability and bloating with a variety of ingredients, including high-potency B vitamins, calcium, magnesium, folic acid and two natural herbal blends, the company stated.

CROMWELL, Conn. — Amerifit Brands on Wednesday launched its Azo PMS product, which has been formulated to help reduce moodiness, irritability and bloating with a variety of ingredients, including high-potency B vitamins, calcium, magnesium, folic acid and two natural herbal blends, the company stated.

May 18, 2011

A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.

WASHINGTON — A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.

Data from the phase-2 study of the drug Rapaflo (silodosin) presented at the American Urological Association’s annual meeting showed that it reduced symptoms and improved outcomes in men with chronic prostatitis/pelvic pain syndrome, also known as CP/CPPS.

April 28, 2011

Drug maker Eli Lilly will get at least two more years of patent exclusivity on a drug used to treat depression, anxiety and pain resulting from diabetic neuropathy and fibromyalgia, thanks to a court order issued Wednesday.

INDIANAPOLIS — Drug maker Eli Lilly will get at least two more years of patent exclusivity on a drug used to treat depression, anxiety and pain resulting from diabetic neuropathy and fibromyalgia, thanks to a court order issued Wednesday.

The U.S. District Court for the Southern District of Indiana ruled to forbid Wockhardt and other generic drug companies from selling generic versions of Cymbalta (duloxetine hydrochloride) until patent protection expires, which is expected to occur in June 2013.

April 7, 2011

The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.

The FDA approved Horizant (gabapentin enacarbil) as a once-daily treatment for moderate-to-severe RLS.

“People with restless legs syndrome can experience considerable distress from their symptoms,” FDA Division of Neurology Products director Russell Katz said. “Horizant provides significant help in treating these symptoms.”

March 8, 2011

The Food and Drug Administration declined to approve a drug made by Salix Pharmaceuticals for irritable bowel syndrome, Salix said Tuesday.

RALEIGH, N.C. — The Food and Drug Administration declined to approve a drug made by Salix Pharmaceuticals for irritable bowel syndrome, Salix said Tuesday.

The FDA issued a complete response letter to Salix for Xifaxan (rifaximin), a treatment for nonconstipation IBS and IBS-related bloating. Salix said it had anticipated that it would receive the letter based on an understanding that the agency needed more information related to retreatment.

January 24, 2011

Advanced Vision Research on Monday announced results from a pilot trial published in the journal Cornea that demonstrated a reduction in dry-eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears Nutrition, an optimized blend of omega-3 oils.

WOBURN, Mass. — Advanced Vision Research on Monday announced results from a pilot trial published in the journal Cornea that demonstrated a reduction in dry-eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears Nutrition, an optimized blend of omega-3 oils.

Almost 3-in-4 symptomatic dry-eye patients who received the omega-3 supplement reported having no symptoms of dry eye after 90 days. In the placebo group, only 7% had a complete reduction of symptoms.

December 16, 2010

An investigational treatment for irritable bowel syndrome could become a blockbuster by the end of the decade, according to a report by Decision Resources.

BURLINGTON, Mass. — An investigational treatment for irritable bowel syndrome could become a blockbuster by the end of the decade, according to a report by Decision Resources.

The report, which the healthcare market research firm said it would publish later this month, found that linaclotide — made by Ironwood Pharmaceuticals, Forest Labs, Almirall and Astellas Pharma — would emerge as the market leader for IBS and achieve sales of $1.1 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan by 2019.

November 29, 2010

A generic drug maker announced that the Food and Drug Administration has granted tentative approval for its version of a popular antidepressant.

MUMBAI, India — A generic drug maker announced that the Food and Drug Administration has granted tentative approval for its version of a popular antidepressant.

Sun Pharmaceutical Industries said the FDA approved its duloxetine hydrochloride delayed-release capsules in 20-mg, 30-mg and 60-mg strengths. The capsules are a generic version of Eli Lilly's Cymbalta, which is indicated to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain.